Answers are grounded in this paper and cite their sources.
Targeted protein degradation of the translation termination factor GSPT1 is a promising cancer strategy. However, current cereblon-recruiting molecular glue degraders (MGDs) lack structural diversity, being mostly IMiD derivatives. To overcome resistance and improve drug-like properties, we report the rational, structure-guided design of a novel series of benzofuran-based GSPT1 MGDs. Extensive structure−activity relationship studies and optimization led to the discovery of highly potent, orally bioavailable degraders, highlighted by compounds C-3 and C-4. Both exhibited single-digit nanomolar GSPT1 degradation (DC50 = 2.81 and 1.91 nM) and robust selectivity over IMiD off-targets IKZF1 and SALL4. In vivo, oral administration (1−2 mg/kg) of C-3 and C-4 demonstrated favorable cross-species pharmacokinetics and achieved sustained tumor regression in NCI-H1155 and MDA-MB-468 xenograft models. With a maximum tolerated dose exceeding 100 mg/kg and no hematological toxicity, these benzofuran-based MGDs are highly promising preclinical candidates for solid tumors.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: